Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
A legfontosabb adatok
- Ki végzi
- Chinese PLA General Hospital
- Hol
- Kína3 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 3. fázis
- Résztvevők
- 146 fő, tervezett
- Kezdés
- 2026. aug. 1.
- Várható befejezés
- 2030. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Lenalidomide
- Placebo
- A regiszteradat frissítve
- 2026. július 22.
Ki vehet részt
- Életkor
- 18 év – 75 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 17 feltétel megnézéseKevesebb
Ki vehet részt
- Adults aged 18 to 75 years at the time of screening
- Diagnosis of IgG4-related disease according to the 2019 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria
- Patients with IgG4-related disease who have achieved sustained clinical remission following glucocorticoid therapy
- No documented IgG4-related disease relapse within the previous 12 months before screening
- IgG4-related disease Responder Index (IgG4-RD RI) score of 0 at screening
- Receiving stable low-dose glucocorticoid therapy with prednisone-equivalent dose ≤7.5 mg/day for at least 6 months before randomization
- Ability to provide written informed consent and comply with study procedures
Ki nem vehet részt
- Previous treatment with lenalidomide or known hypersensitivity to lenalidomide or related compounds
- Requirement for prohibited concomitant medications during the study period
- Significant hepatic or renal dysfunction that may affect study participation or drug safety evaluation
- Active IgG4-related disease requiring induction therapy or escalation of immunosuppressive treatment at screening
- Significant uncontrolled infection or active severe infection
- History of thromboembolic events or conditions associated with unacceptable thrombotic risk according to investigator assessment
- Malignancy or other severe medical conditions that may interfere with study participation or outcome assessment
- Any condition that, in the investigator's opinion, may compromise participant safety or affect the reliability of study results
- Clinically significant hematologic abnormalities, including severe neutropenia or thrombocytopenia
- Pregnancy, breastfeeding, or unwillingness to use effective contraception when applicable
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Immunoglobulin G4-related disease (IgG4-RD) is a chronic immune-mediated disorder characterized by inflammation, fibrosis, and involvement of multiple organs. Although glucocorticoids can effectively induce remission, many patients experience disease relapse after glucocorticoid tapering or discontinuation, and long-term glucocorticoid exposure may cause significant adverse effects. Therefore, new maintenance treatment strategies are needed to reduce relapse risk and minimize glucocorticoid-related toxicity.
A teljes eredeti leírásKevesebb
This study is designed to evaluate the efficacy and safety of lenalidomide as a maintenance therapy in patients with stable IgG4-RD. This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial.
Eligible participants will be adults with IgG4-RD who meet the 2019 ACR/EULAR IgG4-RD classification criteria and are in a stable disease state. Participants will be randomly assigned in a 1:1 ratio to receive either lenalidomide or matching placebo for 52 weeks. All participants will receive standardized glucocorticoid tapering according to the study protocol.
The primary objective of this study is to determine whether lenalidomide can reduce the risk of IgG4-RD relapse compared with placebo. The primary outcome is the proportion of participants experiencing disease relapse within 52 weeks after randomization.
Secondary objectives include evaluation of time to relapse, maintenance of remission, changes in disease activity, quality of life, and safety outcomes. Exploratory assessments will investigate changes in immunological biomarkers, peripheral blood immune profiles, transcriptomic characteristics, and gut microbiota.
This study aims to provide clinical evidence for a new maintenance treatment approach for patients with IgG4-RD and potentially reduce disease recurrence and glucocorticoid exposure.
A vizsgálat 2 csoportja
- Lenalidomide ArmA vizsgált kezelés
Participants will receive lenalidomide 5 mg orally once daily for 52 weeks as maintenance therapy. All participants will undergo standardized glucocorticoid tapering according to the study protocol during the initial treatment period. Lenalidomide will be administered in addition to background glucocorticoid management.
Kezelés: Lenalidomide
- Placebo ArmPlacebo, összehasonlításként
Participants will receive matching placebo orally once daily for 52 weeks as maintenance therapy. All participants will undergo standardized glucocorticoid tapering according to the study protocol during the initial treatment period. The placebo will be identical in appearance, packaging, labeling, and administration procedures to lenalidomide.
Kezelés: Placebo
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase III Multicenter Randomized Double-Blind Placebo-Controlled Study Evaluating the Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
- Kérdések a feltételekről
- Forrás: NCT07719543: ki vehet részt
- A regiszteradat frissítve
- 2026. július 22.